Indore has now established a high-tech COVID care centre, in wake of the soaring rise of infections in the city and the state, at large. Pegged to be the second-largest treatment facility in the country, this centre currently houses 600 beds that can be raised over ten times, to 6,200, if needed. This makeshift amenity expands over 45 acres of land at the Radha Swami Satsang Bhawan and will cater to asymptomatic patients, on the recommendation of the Rapid Response Team.
In-house laboratory for conducting RT-PCR tests
This COVID facility in Indore has been established for the benefit of patients that don’t have respiratory issues and are in need of isolation under medical care. At the same time, certain HDU beds are available here to stabilise patients’ oxygen levels, in case of emergencies. If there are further complications or development of symptoms, the patient will be referred to the nearest dedicated COVID hospitals where a proper bed would be provided to them.
This jumbo facility will also have an in-house laboratory for conducting RT-PCR tests. Other modern facilities such as 2 house oxygen plants are also available here. This equipment costs over ₹2 crores and has been installed via crowdfunding, the Indore Collector informed. Both plants can generate 850 litres of oxygen per minute.
Dedicated medical station for a group of 36 patients
Reportedly, this facility will be compartmentalized into 4 sections and each will be looked after by four hospitals, namely Appollo, Choithram, Bombay and Medanta. A medical and nursing station will be provided for a bunch of 36 patients. A physician, nurse and volunteer will be available at each such desk.
Patients will be allotted cardboard beds that can be easily disposed of after the patient is discharged. This will prevent contact and diminish the chances of spread. A giant LED screen will also be installed here as a recreational means for isolated patients. A temporary police post has also been set up there. A team of officials have been designated to take care of the centre which will soon be operational. Once complete, it will be the second-largest facility in the country.
Fabiflu production begins in full swing
The rising swell of the second wave of COVID-19 has significantly dampened the healthcare and medical infrastructure, creating a shortage of several resources, including treatment faculties such as medical grade oxygen, Remdesivir injections and ventilators. However, circumventing this persistent pandemic scourge, a Glenmark pharma company in Madhya Pradesh’s Pithampur has started the production of Fabiflu, an essential and effective tablet for the virus treatment. This promises a better scenario in Indore, Bhopal and other districts in a day or two, once the stocks are replenished. Other medicinal companies too have started the production and the medicine will be available in sufficient stocks across MP, read reports.
Doctors prescribing Fabiflu medicines to all patients fighting the COVID-19 scare and as result, the demand has risen sharply for the 400 mg and 800 mg variant of these tablets, along with other medicines. Consequently, a shortage of supply here too had added to the people’s trouble due to stringent availability for the last 10 to 12 days but it will be soon eased with domestic production in Madhya Pradesh. Earlier the medicines were being imported from Sikkim where cancellations and other issues delayed the supply at the emergency hour.
What created the medicine shortage?
This targetted supply may also tackle the several ill-practices that are surrounding the availability of Fabiflu.In Indore itself, there are about 45 stockists of Fabiflu and who have informed that while there was no shortage earlier and people hoarded the medicines, resulting in the scarceness now.
Several traders have been accused of allegedly hoarding the medicines to eventually sell in black for higher profits. However, the 3-month short expiry term of the medicine has ruled out these arguments. At the same time, people are also charging way over the market price for the delivery of these tablets, creating hurdles for the already struggling patients and their families. Lack of efforts by the administration to regulate its supplies also added to its overall shortage, the reports added.
